Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non Operating Income: 2012-2025

Historic Non Operating Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$282,000.

  • Enanta Pharmaceuticals' Non Operating Income fell 142.22% to -$282,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 53.88%. This contributed to the annual value of $1.8 million for FY2025, which is 53.88% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Non Operating Income is -$282,000, which was down 142.28% from $667,000 recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Non Operating Income registered a high of $1.9 million during Q2 2023, and its lowest value of -$282,000 during Q3 2025.
  • For the 3-year period, Enanta Pharmaceuticals' Non Operating Income averaged around $992,909, with its median value being $857,000 (2023).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Non Operating Income skyrocketed by 620.39% in 2023 and then slumped by 142.22% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Non Operating Income (Quarterly) stood at $258,000 in 2021, then skyrocketed by 284.88% to $993,000 in 2022, then declined by 13.70% to $857,000 in 2023, then declined by 2.33% to $837,000 in 2024, then plummeted by 142.22% to -$282,000 in 2025.
  • Its Non Operating Income was -$282,000 in Q3 2025, compared to $667,000 in Q2 2025 and $578,000 in Q1 2025.